The company intends to use the funds to continue advancing its MAPS vaccine pipeline for a range of infectious diseases, including its lead pneumococcal vaccine candidates and vaccine candidates targeting healthcare-associated infections where previous vaccine approaches have not been successful.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

301 Binney St. 302
Cambridge, MA 02142
USA

Phone

617-465-0865

Website

www.affinivax.com

Email Address

[email protected]

Overview

Affinivax is developing a next generation vaccine technology platform based on its proprietary platform, the Multiple Antigen Presenting System (MAPS).

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Steven Brugger

Chief Operating Officer

Kamran Tavangar

VP - Finance

Joseph Straight

VP - Human Resources

Ann Straight

VP - Product Management

Shite Sebastian

VP - R & D

Gilles Besin

VP - Regulatory Affairs

Frank Malinoski

Browse more venture capital transactions:

Prev: 1/11/2021: Voxie venture capital transaction
Next: 1/11/2021: LEXEO Therapeutics venture capital transaction

Share this article

About Our VC Transactions Data

Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary